CD8A and colorectal carcinoma: CRIS‐C patients displayed low levels of CD8+ tumor‐infiltrating lymphocytes (TILs), and, notably, 50.2% of the CMS2 CRC patients were divided into CRIS‐C, and the CRIS‐C patients in CMS2 had favorable prognosis with adjuvant chemotherapy (ACT) compared with surgery alone, in stage II and III.35